WCN26-2839 LONG-TERM EFFICACY AND SAFETY OF PERIODIC REPEATED RITUXIMAB ADMINISTRATIONS FOR PEDIATRIC REFRACTORY NEPHROTIC SYNDROME: A MULTICENTER RETROSPECTIVE OBSERVATIONAL STUDY

Rituximab (RTX) is effective in preventing relapse in children with refractory nephrotic syndrome (NS), however most patients eventually relapse after RTX administration. Therefore, repeated RTX administrations and/or additional immunosuppressive therapies are often required, although a standardized RTX protocol has not yet been established. Adverse events such as late-onset agranulocytosis and hypogammaglobulinemia have also been reported, and the long-term safety of RTX therapy remains uncertain.